We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current EDIT market cap is 108.14M. The company's latest EPS is USD -1.8561 and P/E is -0.71.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 5.34M | 60.05M | 1.14M | 514k | 61k |
| Operating Income | -50.16M | -23.96M | -66.99M | -71.9M | -65.67M |
| Net Income | -45.02M | -18.87M | -61.95M | -67.61M | -62.14M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 20.53M | 90.73M | 25.54M | 19.71M | 78.12M |
| Operating Income | -140.92M | -134.84M | -193.15M | -225.95M | -169.18M |
| Net Income | -133.75M | -115.98M | -192.5M | -220.43M | -153.22M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 504.65M | 499.15M | 440.35M | 384.8M | 327.57M |
| Total Liabilities | 144.19M | 150.06M | 145.95M | 152.79M | 151.93M |
| Total Equity | 360.46M | 349.1M | 294.4M | 232.01M | 175.63M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 508.89M | 572.6M | 677.48M | 514.32M | 499.15M |
| Total Liabilities | 246.45M | 179.02M | 123.84M | 153.64M | 150.06M |
| Total Equity | 262.44M | 393.59M | 553.64M | 360.68M | 349.1M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -109.94M | -132.18M | -49.87M | -106.93M | -159.52M |
| Investing | -66.57M | -3.73M | -4.75M | 47.21M | 131.19M |
| Financing | 117.53M | 118.04M | 192k | 514k | 514k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -40.67M | -179.84M | -163.8M | -177.35M | -132.18M |
| Investing | 12.25M | -140.52M | -54.47M | 114.07M | -3.73M |
| Financing | 131.82M | 224.12M | 282.11M | 1.28M | 118.04M |
| Market Cap | 108.14M |
| Price to Earnings Ratio | -0.71 |
| Price to Sales Ratio | 1.38 |
| Price to Cash Ratio | 0.87 |
| Price to Book Ratio | 0.31 |
| Dividend Yield | - |
| Shares Outstanding | 82.55M |
| Average Volume (1 week) | 1.6M |
| Average Volume (1 Month) | 2.38M |
| 52 Week Change | -81.23% |
| 52 Week High | 11.58 |
| 52 Week Low | 1.12 |
| Spread (Intraday) | 0.04 (2.96%) |
| Company Name | Editas Medicine Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.editasmedicine.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
